Guangzhou Innogen Pharmaceutical (HKG:2591) widened its attributable loss in the first half of 2025 to 122.5 million yuan from 75.3 million yuan in the year-ago period, an Aug. 29 filing with the Hong Kong bourse said.
Shares of the pharmaceutical company were down 6% in Monday afternoon trading.
Loss per share rose to 0.29 yuan in the six months from 0.18 yuan in the corresponding period of the last year.
Revenue stood at 56.4 million yuan in the period, mainly from sales of Efsubaglutide Alfa in China.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.